Two Sigma Securities LLC Sells 13,378 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Two Sigma Securities LLC cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 82.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,811 shares of the medical equipment provider’s stock after selling 13,378 shares during the period. Two Sigma Securities LLC’s holdings in Zimmer Biomet were worth $297,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Roman Butler Fullerton & Co. bought a new stake in Zimmer Biomet in the 4th quarter valued at about $473,000. KLCM Advisors Inc. bought a new stake in Zimmer Biomet in the 4th quarter valued at about $7,825,000. Peddock Capital Advisors LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at about $654,000. Van ECK Associates Corp increased its position in Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after buying an additional 218,688 shares in the last quarter. Finally, Reinhart Partners LLC. increased its position in Zimmer Biomet by 34.4% in the 4th quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider’s stock valued at $9,164,000 after buying an additional 22,220 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Royal Bank of Canada decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Stifel Nicolaus lifted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. BTIG Research reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th. JMP Securities reiterated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Raymond James cut their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Trading Up 0.3 %

Shares of ZBH opened at $101.85 on Tuesday. The business has a 50-day moving average of $105.78 and a 200 day moving average of $106.60. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $93.10 and a fifty-two week high of $123.96. The firm has a market cap of $20.15 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the company posted $2.20 earnings per share. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s payout ratio is presently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.